Jun. 30 at 3:16 AM
$NMRA For everyone still holding after KOASTAL: understand what’s happening now.
KOASTAL failed. Navacaprant is dead. Brutal? Yes. Company-killer? No.
The stock flushed to the
$0.80s and has already fought back hard because the market is starting to price the remaining pipeline, not the dead program.
Here’s what’s next:
NMRA-215 — obesity/cardiometabolic
Repeat tox study expected mid-2026, update likely with Q2 earnings in August. If clean, this becomes a serious reset catalyst.
NMRA-898 — schizophrenia
Phase 1 data expected in 2H 2026.
NMRA-511 — Alzheimer’s agitation
Higher-dose cohort expected Q4 2026, Phase 2b planned by year-end.
That’s 3 shots on goal, runway into Q3 2027, and analysts still maintaining bullish targets even after removing KOASTAL.
The story changed. It didn’t end.
Bag holders need to stop staring at KOASTAL’s grave and start watching the next catalysts.
Recovery mode has begun. NFA
